Breaking News

Pharmalucence Wins Lantheus Contract

By Kristin Brooks | December 10, 2013

To manufacture injectable suspension product at new facility

Pharmalucence, Inc. has entered into an agreement with Lantheus Medical Imaging to manufacture DEFINITY Vial for (Perflutren Lipid Microsphere) Injectable Suspension for contrast-enhanced echocardiography. Pharmalucence will provide manufacturing at its new drug production facility in Billerica, MA for a minimum of 10 years. 
Ed Connolly, chief operating officer of Pharmalucence, said, “Pharmalucence has established a world-class manufacturing facility here in New England, which has been recognized by companies who choose to outsource their manufacturing. We are extremely pleased to partner with Lantheus, a local company with a reputation for exceptional product innovation and quality, for the supply of DEFINITY.”
“Our manufacturing agreement with Pharmalucence is a vital component of our plan to secure long-term supply of DEFINITY,” said Jeff Bailey, Lantheus president and chief executive officer. “We look forward to working with Pharmalucence, who has a shared commitment to deliver the highest quality products to the customers and patients who benefit from DEFINITY.”
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks